Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer.

Eichenauer T, Hussein M, Hube-Magg C, Kluth M, Büscheck F, Höflmayer D, Tsourlakis MC, Steurer S, Clauditz TS, Luebke AM, Burandt E, Wilczak W, Hinsch A, Dum D, Beyer B, Steuber T, Huland H, Graefen M, Simon R, Sauter G, Melling N, Schlomm T, Minner S.

Oncotarget. 2019 Mar 1;10(18):1729-1744. doi: 10.18632/oncotarget.26739. eCollection 2019 Mar 1.

2.

p53 overexpression is a prognosticator of poor outcome in esophageal cancer.

Melling N, Norrenbrock S, Kluth M, Simon R, Hube-Magg C, Steurer S, Hinsch A, Burandt E, Jacobsen F, Wilczak W, Quaas A, Bockhorn M, Grupp K, Tachezy M, Izbicki J, Sauter G, Gebauer F.

Oncol Lett. 2019 Apr;17(4):3826-3834. doi: 10.3892/ol.2019.10020. Epub 2019 Feb 6.

3.

Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.

Schroeder C, Grell J, Hube-Magg C, Kluth M, Lang D, Simon R, Höflmayer D, Minner S, Burandt E, Clauditz TS, Büscheck F, Jacobsen F, Huland H, Graefen M, Schlomm T, Sauter G, Steurer S.

BMC Cancer. 2019 Mar 1;19(1):193. doi: 10.1186/s12885-019-5390-1.

4.

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.

Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Li W, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt EC, Steurer S, Wilczak W, Hinsch A.

Dis Markers. 2019 Jan 10;2019:5160565. doi: 10.1155/2019/5160565. eCollection 2019.

5.

5q21 deletion is often heterogeneous in prostate cancer.

Kluth M, Al Kilani Z, Özden C, Hussein K, Frogh S, Möller-Koop C, Burandt E, Steurer S, Büscheck F, Jacobsen F, Luebke AM, Minner S, Tsourlakis MC, Hoeflmayer D, Wittmer C, Schlomm T, Sauter G, Simon R, Wilczak W.

Genes Chromosomes Cancer. 2019 Aug;58(8):509-515. doi: 10.1002/gcc.22730. Epub 2019 Jan 24.

PMID:
30623509
6.

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J.

Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016.

PMID:
30537516
7.

Upregulation of centromere protein F is linked to aggressive prostate cancers.

Göbel C, Özden C, Schroeder C, Hube-Magg C, Kluth M, Möller-Koop C, Neubauer E, Hinsch A, Jacobsen F, Simon R, Sauter G, Michl U, Pehrke D, Huland H, Graefen M, Schlomm T, Luebke AM.

Cancer Manag Res. 2018 Nov 9;10:5491-5504. doi: 10.2147/CMAR.S165630. eCollection 2018.

8.

Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.

Li W, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Pott L, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt E, Steurer S, Wilczak W, Hinsch A.

BMC Cancer. 2018 Dec 4;18(1):1209. doi: 10.1186/s12885-018-5111-1.

9.

Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer.

Kluth M, Volta H, Hussein M, Taskin B, Frogh S, Möller-Koop C, Büscheck F, Jacobsen F, Tsourlakis MC, Lübke AM, Hinsch A, Clauditz T, Graefen M, Heinzer H, Huland H, Minner S, Sauter G, Wilczak W, Schlomm T, Simon R.

Cancer Manag Res. 2018 Nov 19;10:5909-5917. doi: 10.2147/CMAR.S172637. eCollection 2018.

10.

Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer.

Lange T, Oh-Hohenhorst SJ, Joosse SA, Pantel K, Hahn O, Gosau T, Dyshlovoy SA, Wellbrock J, Feldhaus S, Maar H, Gehrcke R, Kluth M, Simon R, Schlomm T, Huland H, Schumacher U.

Sci Rep. 2018 Dec 3;8(1):17535. doi: 10.1038/s41598-018-35695-8.

11.

Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.

Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C.

Prostate. 2019 Feb;79(3):302-311. doi: 10.1002/pros.23736. Epub 2018 Nov 14.

PMID:
30430607
12.

High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases.

Brandi F, Grupp K, Hube-Magg C, Kluth M, Lang D, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wittmer C, Jacobsen F, Huland H, Steurer S, Lebok P, Hinsch A, Wilczak W, Schlomm T, Simon R.

Oncol Lett. 2018 Nov;16(5):6238-6244. doi: 10.3892/ol.2018.9417. Epub 2018 Sep 7.

13.

Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.

Büscheck F, Fraune C, Simon R, Kluth M, Hube-Magg C, Möller-Koop C, Shadanpour N, Bannenberg C, Eichelberg C, Höflmayer D, Clauditz T, Wittmer C, Wilczak W, Sauter G, Fisch M, Rink M, Eichenauer T.

Urol Oncol. 2018 Dec;36(12):531.e19-531.e25. doi: 10.1016/j.urolonc.2018.08.015. Epub 2018 Oct 12.

PMID:
30322727
14.

Author Correction: Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.

Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang DS, Simon R, Beyer B, Thederan I, Sauter G, Izbicki JR, Luebke AM, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Schlomm T, Wilczak W.

Sci Rep. 2018 Aug 21;8(1):12821. doi: 10.1038/s41598-018-30975-9.

15.

13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer.

Kluth M, Scherzai S, Büschek F, Fraune C, Möller K, Höflmayer D, Minner S, Göbel C, Möller-Koop C, Hinsch A, Neubauer E, Tsourlakis MC, Sauter G, Heinzer H, Graefen M, Wilczak W, Luebke AM, Burandt E, Steurer S, Schlomm T, Simon R.

Genes Chromosomes Cancer. 2018 Oct;57(10):504-512. doi: 10.1002/gcc.22645. Epub 2018 Aug 20.

PMID:
29923647
16.

PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.

Heinrich MC, Göbel C, Kluth M, Bernreuther C, Sauer C, Schroeder C, Möller-Koop C, Hube-Magg C, Lebok P, Burandt E, Sauter G, Simon R, Huland H, Graefen M, Heinzer H, Schlomm T, Heumann A.

BMC Cancer. 2018 May 31;18(1):612. doi: 10.1186/s12885-018-4547-7.

17.

Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer.

Neubauer E, Latif M, Krause J, Heumann A, Armbrust M, Luehr C, Fraune C, Hube-Magg C, Kluth M, Möller-Koop C, Sauter G, Simon R, Beyer B, Pompe RS, Thederan I, Schlomm T, Büscheck F.

Exp Mol Pathol. 2018 Aug;105(1):50-56. doi: 10.1016/j.yexmp.2018.05.006. Epub 2018 May 24.

PMID:
29803408
18.

Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer.

Hinsch A, Brolund M, Hube-Magg C, Kluth M, Simon R, Möller-Koop C, Sauter G, Steurer S, Luebke A, Angerer A, Wittmer C, Neubauer E, Göbel C, Büscheck F, Minner S, Wilczak W, Schlomm T, Jacobsen F, Clauditz TS, Krech T, Tsourlakis MC, Schroeder C.

World J Urol. 2018 Jun;36(6):877-882. doi: 10.1007/s00345-018-2225-7. Epub 2018 Feb 9.

PMID:
29427004
19.

Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer.

Kluth M, Jung S, Habib O, Eshagzaiy M, Heinl A, Amschler N, Masser S, Mader M, Runte F, Barow P, Frogh S, Omari J, Möller-Koop C, Hube-Magg C, Weischenfeldt J, Korbel J, Steurer S, Krech T, Huland H, Graefen M, Minner S, Sauter G, Schlomm T, Simon R.

Oncotarget. 2017 Nov 11;8(65):108923-108935. doi: 10.18632/oncotarget.22408. eCollection 2017 Dec 12.

20.

High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.

Heumann A, Heinemann N, Hube-Magg C, Lang DS, Grupp K, Kluth M, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Wittmer C, Jacobsen F, Huland H, Simon R, Schlomm T, Sauter G, Steurer S, Lebok P, Hinsch A.

BMC Cancer. 2018 Jan 5;18(1):37. doi: 10.1186/s12885-017-3956-3.

Supplemental Content

Loading ...
Support Center